News

Intended use update and professional-care market entry targeted for H1 2027 Basel, Switzerland, August 2026 – FiberSense AG (“FiberSense”) today announced plans to expand the clinical application of its new Continuous Glucose Monitoring (CGM) System into selected professional healthcare settings. Following CE marking for the FiberSense CGM System in June,

Major regulatory milestone paves the way for commercialization and marks first step toward FiberSense’s broader CxM biomarker sensing strategy Basel, Switzerland, June 2026 – FiberSense AG (“FiberSense”) today announced that the FiberSense Continuous Glucose Monitoring (CGM) System has obtained CE marking under Regulation (EU) 2017/745 as a Class IIb medical